Prescription of statin and anticoagulant therapy after ischemic stroke was associated with reduced risk of death (HR 0.78, 95% CI 0.65-0.91 and HR 0.58, 95% CI 0.44-0.76, respectively).
Cohort (n=14,529)
Yes
Does the prescription of secondary prevention medications (antiplatelets, ACE inhibitors, statins, anticoagulants) reduce the risk of death in patients with first-ever ischemic stroke?
Statins and anticoagulants are associated with reduced mortality after a first ischemic stroke but are significantly underused in elderly patients.
Hazard Ratio: 0.78 (95% CI 0.65–0.91)
BACKGROUND AND PURPOSE: Secondary prevention is recommended after stroke, but adherence to guidelines is unknown. We studied the prescription of antiplatelet drugs, angiotensin-converting enzyme inhibitors, statins, and anticoagulant drugs and their relation to risk of death. METHODS: Patients with first-ever ischemic stroke in 2005 were registered in the Swedish Stroke Register. Odds ratios, hazard ratios, and 95% CIs were calculated using logistic and Cox proportional hazard regression models. Adjustments were performed for age, sex, cardiovascular risk factors, other drug therapies, and activities of daily living function. RESULTS: In total, 14,529 patients with a mean age of 75.0 (+/-11.6) years were included. They were followed for 1.4 (+/-0.5) years: 52% had hypertension, 26% atrial fibrillation, 19% diabetes, and 15% were smokers. The odds ratio for prescription of antiplatelet was 2.20 (95% CI, 1.86 to 2.60) among the oldest patients (>or=85 years of age) compared with the youngest (18 to 64 years of age). The corresponding odds ratio was 0.38 (0.32 to 0.45) for prescriptions of angiotensin-converting enzyme inhibitors, 0.09 (0.08 to 0.11) for statins, and 0.07 (0.05 to 0.09) for anticoagulant therapy. Prescription of statin and anticoagulant therapy was associated with reduced risk of death (hazard ratio, 0.78 0.65 to 0.91 and hazard ratio, 0.58 0.44 to 0.76, respectively) but not the prescription of antiplatelet drugs or angiotensin-converting enzyme inhibitors. CONCLUSIONS: The prescription of antiplatelet, angiotensin-converting enzyme inhibitors, statins, and anticoagulant therapy was strongly age related. Statin and anticoagulant therapy was associated with reduced risk of death and seemed to be underused among elderly patients. These findings should encourage physicians to follow today's guidelines for stroke care.
Åsberg et al. (Fri,) conducted a cohort in first-ever ischemic stroke (n=14,529). Statin and anticoagulant therapy vs. No prescription was evaluated on death (HR 0.78, 95% CI 0.65-0.91). Prescription of statin and anticoagulant therapy after ischemic stroke was associated with reduced risk of death (HR 0.78, 95% CI 0.65-0.91 and HR 0.58, 95% CI 0.44-0.76, respectively).